Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 14/20 | 0.66 |
| ▸ | NMUR1 | Q9HB89 | 13/20 | 0.66 |
| ▸ | F2R | P25116 | 2/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358974 | 0.91 | F2R (0.70) | NMUR2NMUR1F2RNPY1R | |
| SCHEMBL29519178 | 0.89 | NMUR2 (0.79) | NMUR2NMUR1NPY1RNTSR2NTSR1 | |
| SCHEMBL29733484 | 0.85 | NTSR1 (0.69) | NMUR2NMUR1NPY1RNTSR2NTSR1 | |
| SCHEMBL29359131 | 0.85 | NPY1R (0.69) | NMUR2NMUR1F2RNPY1R | |
| SCHEMBL27076913 | 0.85 | NPY1R (0.69) | NMUR2NMUR1F2RNPY1R | |
| SCHEMBL29698606 | 0.84 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL29370026 | 0.84 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL3539226 | 0.84 | NMUR2 (0.71) | NMUR2NMUR1 | |
| SCHEMBL29493537 | 0.84 | NTSR1 (0.70) | NMUR2NMUR1NTSR2NTSR1 | |
| SCHEMBL38665589 | 0.84 | NMUR2 (0.61) | NMUR2NMUR1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118136645-B | Device for reducing crosstalk of UTBB pixel unit | 北京大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-118136645-A | Device for reducing crosstalk of UTBB pixel unit | 北京大学 | 2024-06-04 | — | — | CN | disclosed |
| US-11939563-B2 | Continuous automated perfusion culture analysis system (CAPCAS) and applications of same | VANDERBILT UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| EP-3596105-B1 | LIGANDS FOR INTEGRIN .ALPHA.V.BETA.8, SYNTHESIS AND USES THEREOF | UNIV MUENCHEN TECH (DE) | 2023-12-27 | — | — | EP | disclosed |
| CN-115980216-A | Trace methane gas hydrogen isotope detection device and method | 自然资源部第三海洋研究所 | 2023-04-18 | — | — | CN | disclosed |
| US-20230019924-A1 | CONTINUOUS AUTOMATED PERFUSION CULTURE ANALYSIS SYSTEM (CAPCAS) AND APPLICATIONS OF SAME | VANDERBILT UNIVERSITY | 2023-01-19 | — | — | US | disclosed |
| CN-218157431-U | Optical sensing equipment for detecting particles in high-temperature and high-pressure environment | 兰州理工大学 | 2022-12-27 | — | — | CN | disclosed |
| US-11447734-B2 | Continuous automated perfusion culture analysis system (CAPCAS) and applications of same | VANDERBILT UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| US-11332498-B2 | Ligands for integrin αVβ8, synthesis and uses thereof | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2022-05-17 | — | — | US | disclosed |
| US-20220135925-A1 | CONTINUOUS AUTOMATED PERFUSION CULTURE ANALYSIS SYSTEM (CAPCAS) AND APPLICATIONS OF SAME | VANDERBILT UNIVERSITY | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332498-B2 | Ligands for integrin αVβ8, synthesis and uses thereof | ITGB3, ITGB8, ITGA8 | NMUR2 472/4885NMUR1 349/4885F2R 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.